News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Sandoz Group
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
August 12, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
August 07, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
July 30, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
July 01, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
June 02, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
May 21, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
April 30, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
April 29, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 15, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
March 31, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports strong FY 2024 results and Q4 2024 sales
March 05, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
February 24, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Francisco Ballester to retire; Peter Stenico appointed President Region International
February 03, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
December 17, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
November 15, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports third-quarter and nine-month 2024 sales
October 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
October 11, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
August 12, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports second-quarter sales and half-year 2024 results
August 08, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
July 25, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
July 01, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reports first quarter 2024 sales
May 07, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
March 21, 2024
From
Sandoz Group
Via
GlobeNewswire
Tickers
SDZNY
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.